WO2023230711A1 - Lipid nanoparticle for the delivery of rna - Google Patents
Lipid nanoparticle for the delivery of rna Download PDFInfo
- Publication number
- WO2023230711A1 WO2023230711A1 PCT/CA2023/050735 CA2023050735W WO2023230711A1 WO 2023230711 A1 WO2023230711 A1 WO 2023230711A1 CA 2023050735 W CA2023050735 W CA 2023050735W WO 2023230711 A1 WO2023230711 A1 WO 2023230711A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lipid nanoparticle
- lipid
- rna
- peptide
- glycero
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title claims abstract description 96
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 81
- 238000012384 transportation and delivery Methods 0.000 title claims abstract description 41
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 45
- -1 cationic lipid Chemical class 0.000 claims abstract description 25
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 12
- 108020004459 Small interfering RNA Proteins 0.000 claims description 56
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 42
- 150000001413 amino acids Chemical group 0.000 claims description 31
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 230000001225 therapeutic effect Effects 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 230000008685 targeting Effects 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 8
- 229930182558 Sterol Natural products 0.000 claims description 8
- 235000003702 sterols Nutrition 0.000 claims description 8
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 7
- 235000012000 cholesterol Nutrition 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 4
- 230000002209 hydrophobic effect Effects 0.000 claims description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 150000003432 sterols Chemical class 0.000 claims description 4
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000004055 small Interfering RNA Substances 0.000 claims description 3
- HRTBOPUWPUXROO-VCZQVZGSSA-N (2-{[(2r)-2,3-bis(docosanoyloxy)propyl phosphonato]oxy}ethyl)trimethylazanium Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC HRTBOPUWPUXROO-VCZQVZGSSA-N 0.000 claims description 2
- YKIOPDIXYAUOFN-YACUFSJGSA-N (2-{[(2r)-2,3-bis(icosanoyloxy)propyl phosphonato]oxy}ethyl)trimethylazanium Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC YKIOPDIXYAUOFN-YACUFSJGSA-N 0.000 claims description 2
- LZLVZIFMYXDKCN-QJWFYWCHSA-N 1,2-di-O-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC LZLVZIFMYXDKCN-QJWFYWCHSA-N 0.000 claims description 2
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 2
- QGWBEETXHOVFQS-UHFFFAOYSA-N 6-[6-(2-hexyldecanoyloxy)hexyl-(4-hydroxybutyl)amino]hexyl 2-hexyldecanoate Chemical compound CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCO)CCCCCCOC(=O)C(CCCCCC)CCCCCCCC QGWBEETXHOVFQS-UHFFFAOYSA-N 0.000 claims description 2
- 241000945470 Arcturus Species 0.000 claims description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 2
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 claims description 2
- 101000823778 Homo sapiens Y-box-binding protein 2 Proteins 0.000 claims description 2
- RJECHNNFRHZQKU-UHFFFAOYSA-N Oelsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCCCCCCCC)C2 RJECHNNFRHZQKU-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 108091029810 SaRNA Proteins 0.000 claims description 2
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 2
- 108020004566 Transfer RNA Proteins 0.000 claims description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 2
- VEBQYSNFOGTNHW-CLFAGFIQSA-N [4-[2-[2-[1-[2-[2-[4-[2-[2-[4-[(Z)-octadec-9-enoyl]oxyphenyl]acetyl]oxyethyl]piperidin-1-yl]ethyldisulfanyl]ethyl]piperidin-4-yl]ethoxy]-2-oxoethyl]phenyl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)Oc1ccc(CC(=O)OCCC2CCN(CCSSCCN3CCC(CCOC(=O)Cc4ccc(OC(=O)CCCCCCC\C=C/CCCCCCCC)cc4)CC3)CC2)cc1 VEBQYSNFOGTNHW-CLFAGFIQSA-N 0.000 claims description 2
- ZFFZMGJMZGAGMF-SXAUZNKPSA-N [7-[4-(dipropylamino)butyl]-7-hydroxy-13-[(Z)-octadec-9-enoyl]oxytridecyl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCCCCCC(O)(CCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC)CCCCN(CCC)CCC ZFFZMGJMZGAGMF-SXAUZNKPSA-N 0.000 claims description 2
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- CVXBEEMKQHEXEN-UHFFFAOYSA-N carbaryl Chemical compound C1=CC=C2C(OC(=O)NC)=CC=CC2=C1 CVXBEEMKQHEXEN-UHFFFAOYSA-N 0.000 claims description 2
- 229960005286 carbaryl Drugs 0.000 claims description 2
- 150000001840 cholesterol esters Chemical class 0.000 claims description 2
- RJECHNNFRHZQKU-RMUVNZEASA-N cholesteryl oleate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C1 RJECHNNFRHZQKU-RMUVNZEASA-N 0.000 claims description 2
- BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 claims description 2
- NFRFUGBXJTXTMZ-QYKZUBHNSA-L disodium;[(2r)-2,3-di(hexadecanoyloxy)propyl] phosphate Chemical compound [Na+].[Na+].CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])([O-])=O)OC(=O)CCCCCCCCCCCCCCC NFRFUGBXJTXTMZ-QYKZUBHNSA-L 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- 125000005647 linker group Chemical group 0.000 claims description 2
- 108091070501 miRNA Proteins 0.000 claims description 2
- 239000002679 microRNA Substances 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 150000008105 phosphatidylcholines Chemical class 0.000 claims description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 2
- 229940067605 phosphatidylethanolamines Drugs 0.000 claims description 2
- 150000003141 primary amines Chemical class 0.000 claims description 2
- 229940078677 sarna Drugs 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 150000003335 secondary amines Chemical class 0.000 claims description 2
- 239000002356 single layer Substances 0.000 claims description 2
- 150000003512 tertiary amines Chemical class 0.000 claims description 2
- 150000003573 thiols Chemical class 0.000 claims description 2
- BGNVBNJYBVCBJH-UHFFFAOYSA-N SM-102 Chemical compound OCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCCCC(OCCCCCCCCCCC)=O BGNVBNJYBVCBJH-UHFFFAOYSA-N 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 47
- 210000004185 liver Anatomy 0.000 description 22
- 230000001086 cytosolic effect Effects 0.000 description 19
- 206010027476 Metastases Diseases 0.000 description 17
- 108091005487 SCARB1 Proteins 0.000 description 16
- 230000009401 metastasis Effects 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- 238000009472 formulation Methods 0.000 description 14
- 238000003197 gene knockdown Methods 0.000 description 12
- 108060001084 Luciferase Proteins 0.000 description 11
- 239000005089 Luciferase Substances 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 206010009944 Colon cancer Diseases 0.000 description 10
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 210000000172 cytosol Anatomy 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000029918 bioluminescence Effects 0.000 description 8
- 238000005415 bioluminescence Methods 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 6
- 101000941029 Homo sapiens Endoplasmic reticulum junction formation protein lunapark Proteins 0.000 description 6
- 101000991410 Homo sapiens Nucleolar and spindle-associated protein 1 Proteins 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 5
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 230000009368 gene silencing by RNA Effects 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 210000003463 organelle Anatomy 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000004624 confocal microscopy Methods 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000002831 pharmacologic agent Substances 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 3
- 238000011579 SCID mouse model Methods 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000004700 cellular uptake Effects 0.000 description 3
- 238000001142 circular dichroism spectrum Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 230000012202 endocytosis Effects 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 150000004032 porphyrins Chemical class 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 102000007592 Apolipoproteins Human genes 0.000 description 2
- 108010071619 Apolipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 101000752221 Homo sapiens Rho guanine nucleotide exchange factor 2 Proteins 0.000 description 2
- 206010027457 Metastases to liver Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 102100021707 Rho guanine nucleotide exchange factor 2 Human genes 0.000 description 2
- NRLNQCOGCKAESA-KWXKLSQISA-N [(6z,9z,28z,31z)-heptatriaconta-6,9,28,31-tetraen-19-yl] 4-(dimethylamino)butanoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC\C=C/C\C=C/CCCCC NRLNQCOGCKAESA-KWXKLSQISA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000010226 confocal imaging Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- TXLHNFOLHRXMAU-UHFFFAOYSA-N 2-(4-benzylphenoxy)-n,n-diethylethanamine;hydron;chloride Chemical compound Cl.C1=CC(OCCN(CC)CC)=CC=C1CC1=CC=CC=C1 TXLHNFOLHRXMAU-UHFFFAOYSA-N 0.000 description 1
- 101150037123 APOE gene Proteins 0.000 description 1
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101150027967 CRC gene Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101100055841 Danio rerio apoa1 gene Proteins 0.000 description 1
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 238000010870 STED microscopy Methods 0.000 description 1
- 102100037118 Scavenger receptor class B member 1 Human genes 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 241000021375 Xenogenes Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000003349 alamar blue assay Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 230000006395 clathrin-mediated endocytosis Effects 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229960000740 enrofloxacin Drugs 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- IBDXZWQCLMSDKQ-FDXOKOSPSA-N i-cholesterol Chemical compound C([C@H]1[C@@H]2CC[C@@H]([C@]2(CC[C@@H]1[C@@]1(C)CC2)C)[C@H](C)CCCC(C)C)[C@@H](O)[C@@]31[C@H]2C3 IBDXZWQCLMSDKQ-FDXOKOSPSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000006674 lysosomal degradation Effects 0.000 description 1
- 230000034701 macropinocytosis Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940127249 oral antibiotic Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091005484 scavenger receptor class B Proteins 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Definitions
- the invention relates to lipid nanoparticles and more particularly to lipid nanoparticles that deliver RNA to a subject.
- CRC colorectal cancer
- NEPC metastatic neuroendocrine PCa
- RNA platforms are an exciting addition to the toolkit of targeted gene therapies. They function through the delivery of curative RNAs to the cell cytosol, where they regulate expression level of critical disease-related RNA transcripts or proteins. 45 This delivery is mediated by vehicles that protect RNAs from their otherwise rapid degradation in viva, Lipid nanoparticles (LNP) are one such vehicle. LNPs protect RNAs by housing RNAs within their core while circulating through the body. Upon reaching cells, LNPs are uptaken into endosomes, where they dissociate and subsequently release RNA into cytosols.
- LNP Lipid nanoparticles
- SR-B1 Scavenger receptor class B type I
- HDL high-density lipoprotein
- 12 SR-B1 is upregulated in many cancer cell lines. 13 For example, SR-B1 high expression was observed in PCa versus benign prostate, as well as in NEPC versus CRPC, 14 and elevated SR-B1 has been associated to PCa aggressiveness. 15 Besides, increased SRB1 expression in liver metastasis from CRC and breast cancer have also been reported.
- SRBI Due to its upregulation in many cancer cell lines and capacity to induce cytosolic cargo delivery, SRBI becomes a promising surface receptor for targeted cancer therapy with RNA interference.
- Apolipoprotein A-1 (ApoA-1) mimetic peptide R4F into HDL-like nanoparticles, enhanced cytosolic siRNA delivery and in vivo oncogene knockdown have been observed 18 19 .
- this delivery platform is limited by extra cholesterol modification on siRNA to enable siRNA incorporation onto nanoparticle’s lipid membrane via cholesterol overhang, which makes hydrophilic siRNA double strands facing outwards of nanoparticle surface, thus less protected and highly detachable during in vivo circulation.
- a lipid nanoparticle for the delivery of RNA to a subject, the lipid nanoparticle comprising: (a) at least one phospholipid; (b) an ionisable or cationic lipid; (c) a PEG-lipid; (d) at least one peptide, the peptide comprising an amino acid sequence capable of forming at least one amphipathic a-helix; and (e) the RNA; wherein the components a), b), c), d) and e) associate to form the lipid nanoparticle.
- a method of delivering RNA to a subject comprising administering to the subject the lipid nanoparticle described herein.
- the lipid nanoparticle described herein for use in the delivery of RNA to a subject.
- lipid nanoparticle described herein in the preparation of a medicament for treating a disease or condition, wherein the RNA treats said disease or condition.
- lipid nanoparticle in the preparation of a medicament for treating a disease or condition wherein the lipid nanoparticle treats said disease or condition.
- composition comprising the lipid nanoparticle described herein in a pharmaceutically acceptable carrier.
- Figure 1 shows (A) Schematic illustration of siRNA encapsulation, LNP synthesis and R4F modification. (B) Transmission electronic microscopy images of R4F-LNP. (C) Number-based size distribution of R4F-LNP measured by dynamic light scattering. (D) Circular dichroism spectrum of conventional LNP and R4F-LNP, affirming the secondary structures assembled on the R4F-LNP.
- FIG. 2 shows (A) Intracellular delivery profile of R4F-LNP and conventional LNP in PC3-Luc6 at 6 and 24 h post-incubation.
- R4F-LNP displayed stronger cytosolic distribution of siRNA signal. Fluorescence was pseudocolored in green for FAM- labelled siRNA, Magenta for porphyrin-lipid. Scale bar: 20 pm.
- Figure 3 shows in vitro luciferase knockdown by R4F-LNP and conventional LNP.
- PC3-Luc6 cells were seeded in 96-well plates and treated for 48 hours with the indicated doses of siLuc or siCtrl in different formulations. The bioluminescence was captured by Xenogene imaging system.
- B Normalized bioluminescence expression from each treatment group based on cell viability. **: p ⁇ 0.0021 ; ****: p ⁇ 0.0001.
- C Viability of cells treated by each formulation.
- Figure 4 shows cell uptake of R4F-LNP and convention LNP measured by flow cytometry.
- PC3-Luc6 were incubated with both formulations for 6 and 24 h before analyzed by flow cytometer for single cell fluorescence from porphyrin-lipid (A) and FAM-siRNA (B). After 24 h incubation, no significant difference in cellular uptake was observed between formulations.
- Figure 5 shows (A) Experimental design of R4F-LNP siRNA treatment in mouse liver metastasis model. (B) Representative images of the NOD/SCID mouse livers harvested 16 days after treatment with R4F-LNP loaded with different sequences. Quantification of the liver weight at the experimental endpoint in mouse liver metastasis model was shown on the right.
- RNA cytosolic delivery through SRBI-mediated uptake pathway to address the RNA endosomal escape challenge of LNP.
- ApoA-1 mimetic R4F peptide Ac- FAEKFKEAVKDYFAKFWD
- R4F-LNP Figure 1A
- the RNAs are encapsulated in the core of lipid nanoparticles and further shielded by a R4F peptide network thereby being well protected during in vivo circulation.
- R4F-LNP improved siRNA delivery over original LNP formulation with a 3 ⁇ 4-fold enhancement in luciferase reporter gene knockdown efficacy.
- Confocal microscopy imaging revealed that R4F-LNP significantly altered siRNA intracellular delivery profile, showing a transition from classic organelle-oriented endocytosis to direct cytosolic distribution.
- RPC colorectal cancer
- a lipid nanoparticle for the delivery of RNA to a subject, the lipid nanoparticle comprising: at least one phospholipid; an ionisable or cationic lipid; a PEG-lipid; at least one peptide, the peptide comprising an amino acid sequence capable of forming at least one amphipathic a-helix; and the RNA; wherein the components a), b), c), d) and e) associate to form the lipid nanoparticle.
- Suitable scaffold peptides may be selected from the group consisting of Class A, H, L and M a-helices or a fragment thereof. Suitable scaffold peptides may also comprise a reversed peptide sequence of the Class A, H, L and M amphipathic a-helices or a fragment thereof, as the property of forming an amphipathic a-helix is determined by the relative position of the amino acid residues within the peptide sequence.
- the scaffold peptide has an amino acid sequence comprising consecutive amino acids of an apolipoprotein, preferably selected from the group consisting of apoB-100, apoB-48, apoC, apoE and apoA.
- amino acids used in this invention, and the term as used in the specification and claims, include the known naturally occurring protein amino acids, which are referred to by both their common three letter abbreviation and single letter abbreviation. See generally Synthetic Peptides: A User's Guide, G A Grant, editor, W.H. Freeman & Co., New York, 1992, the teachings of which are incorporated herein by reference, including the text and table set forth at pages 11 through 24.
- amino acid also includes stereoisomers and modifications of naturally occurring protein amino acids, non-protein amino acids, post-translationally modified amino acids, enzymatically synthesized amino acids, derivatized amino acids, constructs or structures designed to mimic amino acids, and the like.
- Alpha-helix is used herein to refer to the common motif in the secondary structure of proteins.
- alpha helices made from naturally occurring amino acids will be right handed but left handed conformations are also known.
- amphipathic is a term describing a chemical compound possessing both hydrophilic and hydrophobic properties.
- An amphipathic alpha helix is an often-encountered secondary structural motif in biologically active peptides and proteins and refers to an alpha helix with opposing polar and nonpolar faces oriented along the long axis of the helix.
- small amphipathic helix peptides include those described in WO 09/073984.
- Segrest et al. have identified seven different classes of amphipathic helices and have identified peptides/proteins associated with each class. Of the seven different classes there are four lipid-associating amphipathic helix classes (A, H, L, and M). Of these, Class A, the designated apolipoprotein class, possesses optimal properties for forming phospholipid-based particles.
- phospholipid is a lipid having a hydrophilic head group having a phosphate group and hydrophobic lipid tail.
- PEG-lipid or PEG lipid is also known as PEGylated lipid, and is a class of PEG derivatives that is attached with lipid moiety such as, but not limited to, DMG, DSPE, DPPE, or DMPE.
- the lipid nanoparticle is a monolayer particle comprising the phospholipid, the PEG-lipid and the peptide having encapsulated therein the RNA and ionisable lipid.
- the at least one amphipathic a-helix or peptide is between 6 and 30 amino acids in length.
- the at least one amphipathic a-helix or peptide is between 8 and 28 amino acids in length, between 10 and 24 amino acids in length, between 11 and 22 amino acids in length, between 14 and 21 amino acids in length, between 16 and 20 amino acids in length, or 18 amino acids in length.
- the peptide is 2F, 4F, the reverse sequence of 2F, or the reverse sequence of 4F.
- the total lipid to peptide molar ratio is 0.5-10%.
- the phospholipid is selected from the group consisting of phosphatidylcholines, phosphatidylethanolamines, phosphatidic acid, phosphatidylglycerols and combinations thereof.
- the phospholipid is selected from the group consisting of 1 ,2-dipalmitoyl-sn-glycero-3-phosphatidic acid (DPPA), 1 ,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC), 1 ,2-distearoyl-sn- glycero-3-phosphocholine (DSPC), 1 ,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1 ,2-dibehenoyl-sn-glycero-3-phosphocholine (DBPC), 1 ,2-diarachidoyl-sn- glycero-3-phosphatidylcholine (DAPC), 1 ,2-diarachidoyl
- a headgroup of the ionisable or cationic lipid comprises an amine, guanidine or heterocyclic group.
- the headgroup is a primary amine, secondary amine, tertiary amine, quarternary amine, guanidine, pryidinium or imdazolium.
- the ionisable or cationic lipid comprises 1-4 hydrophobic tails that are independently saturated or unsaturated.
- the ionisable or cationic lipid comprises a linker between the headgroup and tail comprising an ether, carbomate, ester, amide, disulfide, thiol, ketal, phosphate or urea.
- the ionisable or cationic lipid is L319, YSK12-C4, CL4H6, SM- 102, ALC-0315, Arcturus 10q, DLin-DMA-MC3, or ssPalmO-Phe. In some embodiments, the ionisable lipid is present at a 20-90% molar ratio in the lipid nanoparticle.
- the PEG-lipid has a carbon chain length of C14-C22.
- the PEG-lipid has a molecular weight ranging from about 1000 to about 5000.
- the PEG-lipid is 1 ,2-dimyristoyl-rac-glycero-3- methoxypolyethylene glycol-2000 (DMG-PEG2000), N-(methoxypolyethylene glycol 5000 carbamoyl)-1 ,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine (MPEG5000- DPPE), 1 ,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000 (DMPE-PEG2000), 1 ,2-distearoyl-sn-glycero-3-phosphoethanolamine- N- [methoxy(polyethylene glycol)-2000 (DSPE-PEG2000), Polyoxyethylene 40 stearate (PEG40S) or combinations thereof.
- DMG-PEG2000 DMG-PEG2000
- MPEG5000- DPPE N-(methoxypolyethylene glycol 5000 carbamoyl)-1
- the PEG-lipid is present at a 0.5-10% molar ratio in the lipid nanoparticle
- the RNA is a therapeutic RNA.
- the RNA is a siRNA, mRNA, shRNA, miRNA, tRNA, circRNA or saRNA.
- the lipid nanoparticle further comprises a sterol, a sterol ester, or combinations thereof.
- the sterol or a sterol ester is cholesterol, cholesterol oleate or an unsaturated cholesterol-ester.
- the lipid nanoparticle comprises Dlin-MC3-DMA, DSPC, cholesterol, and DMG-PEG2000.
- the lipid nanoparticle further comprises a targeting or homing molecule.
- Targeting molecule is any molecule that can direct the nanovesicle to a particular target, for example, by binding to a receptor or other molecule on the surface of a targeted cell.
- Targeting molecules may be proteins, peptides, nucleic acid molecules, saccharides or polysaccharides, receptor ligands or other small molecules.
- the degree of specificity can be modulated through the selection of the targeting molecule.
- antibodies typically exhibit high specificity. These can be polyclonal, monoclonal, fragments, recombinant, or single chain, many of which are commercially available or readily obtained using standard techniques.
- the lipid nanoparticle further comprises a porphyrinphospholipid conjugate.
- in the lipid nanoparticle is 20-70 nm in diameter, 30-60 nm in diameter or 40-50 nm in diameter.
- RNA delivery RNA comprising administering to the subject the lipid nanoparticle described herein.
- lipid nanoparticle described herein for use in the delivery of RNA to a subject.
- lipid nanoparticle described herein in the preparation of a medicament for treating a disease or condition, wherein the RNA treats said disease or condition.
- composition comprising the lipid nanoparticle described herein in a pharmaceutically acceptable carrier.
- “pharmaceutically acceptable carrier 1 ' means any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible.
- pharmaceutically acceptable carriers include one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof.
- isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition.
- Pharmaceutically acceptable carriers may further comprise minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers, which enhance the shelf life or effectiveness of the pharmacological agent.
- therapeutically effective amount refers to an amount effective, at dosages and for a particular period of time necessary, to achieve the desired therapeutic result.
- a therapeutically effective amount of the pharmacological agent may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the pharmacological agent to elicit a desired response in the individual.
- a therapeutically effective amount is also one in which any toxic or detrimental effects of the pharmacological agent are outweighed by the therapeutically beneficial effects.
- siLuc sense, 5'-GAU UAU GUC CGG UUA UGU AdTsdT-3'; antisense, 5'-UAC AUA ACC GGA CAU AAU CdTsdT-3'.
- FAM-siLuc sense, 5'-FAM-GAU UAU GUC CGG UUA UGU AdTsdT-3'; antisense, 5'-UAC AUA ACC GGA CAU AAU CdTsdT-3'.
- siCtrl (sense, 5’-UUC UCC GAA CGU GUC ACG UdTsdT-3’; antisense, 5’-ACG UGA CAC GUU CGG AGA AdTsdT-3’).
- siRNA targeting ARHGEF2 was purchased from GenePharma (Shanghai, China).
- siARHGEF2 (sense, 5’-GGA UCU ACC UGU CAC UAC Utt-3’; antisense, 5’- AGUAGUGACAGGUAGAUCCag-3’).
- LNPs were passed through 0.22 um filter and concentrated using centrifuge.
- DSPC in the formulation was fully replaced by porphyrin-lipid and siRNA was fluorescein-labelled siRNA was used.
- Formulations were prepared with the same method as described above. 2) R4F- peptide was dissolved in PBS and added dropwise into pre-formed LNP solutions under gentle shaking at a lipid/R4F ratio of 3:1. The mixture was kept at 4 °C overnight. Next, the solution was centrifuged at 12000 rpm for 20 min and filtered with 0.22 um filter before use. The hydrodynamic size and dispersity of R4F-LNP was characterized with a Zetasizer Nano ZS (Malvern Instruments).
- R4F-LNP The morphology of R4F-LNP was checked by Hitachi HT7800 electron microscopy with 2% uranyl acetate negative staining. siRNA encapsulation efficiency was measured by Ribogreen Assay based on manufacture’s protocol (Thermofisher). The circular dichroism spectrum was measured with Jasco J-815 CD spectrophotometer (Jasco, Easton, MD). Formulations diluted in PBS was subjected to scanning from 250 nm to 190 nm at 0.1 nm data pitch with background subtracted.
- PC3-luc6 cells were purchased from Caliper LifeSciences and cultured in Ham's F-12K (Kaighn's) Medium (supplemented with 10% FBS).
- Chinese hamster ovary (CHO) Idl(mSR-BI) and ldlA-7 cells were gifts from Dr. Monty Krieger (Massachusetts Institute of Technology, Cambridge, MA).
- ldlA-7 cells were cultured in Hams F-12 medium (Gibco) supplemented with penicillin-streptomycin (1 v/v %), FBS (5 v/v%), and L-glutamine (2 mM).
- Idl(mSR-BI) cells were cultured under similar conditions as ldlA-7 with the addition of 300 ug/mL of G418 Geneticin.
- HCT116 were purchased from ATCC and cultured in McCoy's 5a Medium Modified with 10% FBS. All cell cultures were maintained in a 37 °C humidified incubator under 5% CO 2 .
- Fluorescence images were captured by Stimulated emission depletion (STED) microscopy (Leica, Germany) using a 63x oil objective lens. Customized filter settings were used to collect signal from porphyrin-lipid (excitation: 660 nm; emission: 670 nm - 765 nm), and FAM-labelled siRNA (excitation: 488 nm; emission: 507-580 nm). Laser power and detector gain adjustment were kept consistent between the time points. For flow cytometry experiments, PC3-Luc6 cells were seeded at 4 x 10 4 cells per well into 24-well plates for 48 h.
- PC3-Luc6 cells were seeded at 4 x 10 3 cells per well into 96-well plates for 48 h. Then cells were incubated with R4F-LNP or pyro-LNP at different siRNA concentration for 48 h, after which the cells were washed twice with culturing medium and replaced with medium that contains 0.5 mg.mL -1 alamarBlue (Invitrogen) for viability measurement: cells were incubated for 2 h, after which fluorescence emission was collected using a CLARIOstar microplate reader (BMG LABTECH) (excitation of 540/8 nm and emission of 590/8 nm).
- Luciferase expression of PC3-Luc6 on the same plate was evaluated through bioluminescence: after alamarBlue assay, 5 pL D-luciferin solution (25 mM) was added into each well (100 pL medium), after which the bioluminescence was collected by IVIS Spectrum In Vivo Imaging System (PerkinElmer). Bioluminescence intensity of each well was further normalized by its viability before analysis.
- mice were established by intrasplenic injection of HCT116 cells into NOD/SCID mouse.
- enrofloxacin in the drinking water as a prophylactic oral antibiotic was administered to mice 72 h prior to surgery.
- Mice were anesthetized with Buprenorphine Sustained-Release (SR). ⁇ 1 cm incision was made in the left upper abdominal wall and ⁇ 1 cm incision was made in the peritoneum to expose the mouse spleen. Moistened sterile cotton swab was used to gently exteriorize the spleen.
- SR Buprenorphine Sustained-Release
- HCT116 cells (0.75x10 6 cells per mouse) were injected into each mouse with a 27G needle. After the spleen was returned to the abdominal cavity, the muscle layer and skin were closed, and subcutaneous fluid therapy was administered. The mice were sacrificed 3 ⁇ 4 weeks after intrasplenic injection. The mouse liver was excised and fixed for histological examination. The liver metastasis was assessed either by the number of visible liver metastatic nodules or the liver weight and the proportion of tumor metastases in the mouse liver when tumor nodules were indistinguishable. Results and Discussion
- R4F-LNP was formulated by coating ApoA-1 mimetic peptide R4F onto the preformed LNP following a process illustrated in Figure 1A. Briefly, LNP nanoparticles were prepared through rapid mixing of siRNA and lipid components via a microfluidic system, followed by raising pH from 4.0 to 7.4 with dialysis process. The R4F peptides were then added dropwisely into the preformed LNPs in PBS condition with a R4F/lipid ratio of 1 :3 and subsequently incubated at 4°C overnight to form stable R4F-LNPS.
- R4F-LNP The morphology of R4F-LNP was disclosed by transmission electronic microscopy imaging ( Figure 1 B), showing spherical structures with homogenous size distribution at ⁇ 50 nm.
- the size of R4F- LNP was also confirmed by dynamic light scattering measurement, showing a monodispersed peak at 45.22 ⁇ 2.18 nm, with a polydispersity index (PDI) of 0.146 ( Figure 1C).
- PDI polydispersity index
- the size of R4F-LNP is in line with that of the LNP ( ⁇ 40-50 nm) before adding R4F, 23 suggesting a surface coating of R4F doesn’t change the particles size.
- both R4F-LNP and conventional LNP were formulated with porphyrin-lipid dopped onto lipid bilayer and FAM dye labelled on siRNA as markers for lipids and siRNA.
- FAM dye labelled on siRNA markers for lipids and siRNA.
- FIG. 2A conventional LNP treated cells (bottom panels) displayed well-colocalized FAM-siRNA and porphyrin-lipid signals with punctate pattern in cells after 6 h incubation, indicating LNP entrapment in acidic organelles (i.e.
- R4F-LNP treated cells showed strong siRNA fluorescence (FAM, green colour) in both cytosols and organelles.
- FAM siRNA fluorescence
- the FAM signal in the cytosols was well diffused.
- the porphyrin lipid fluorescence magenta colour was observed on cellular membrane in addition to co- localization with FAM-siRNA in the same organelles with a punctate pattern.
- R4F-LNP enhanced bioluminescence signal reduction was achieved by R4F-LNP treatment when compared to the conventional LNP across all siRNA concentrations applied.
- R4F-LNP caused ⁇ 70% decrease of bioluminescence expression in PC3- Luc6 cells at 10 nM siLuc concentration whereas only ⁇ 20% knockdown was achieved by conventional LNP without R4F coating, resulting in 3-4 fold therapeutic enhancement.
- the significantly enhanced luciferase knockdown by R4F-LNP is possibly contributed by cytosolic delivery of siRNA that was demonstrated in previous confocal imaging studies.
- mice liver metastasis model was established by injecting 7.5x10 5 HCT116 cells intrasplenically into each NOD/SCID mouse. At twelve days after surgery, the mice were randomly defined into two groups and received 1.2 mg/kg of R4F-LNP siCtrl or R4F-LNP siARHGEF2-1 intravenously, every four days for total four doses (at day12, day 16, day20, day24) (Figure 5A).
- this study first demonstrates the therapeutic potential of applying R4F peptide to FDA-approved lipid nanoparticle formulations for enhancing cytosolic delivery of siRNA therapeutics.
- the R4F-LNP exhibited a combined delivery pattern enabling direct delivery of a portion of siRNA into cancer cell cytosol via a SR- B1 mediated internalization pathway.
- a 3 ⁇ 4-fold enhancement of RNAi therapeutic efficacy by R4F-LNP was demonstrated on an in vitro luciferase expressing prostate cancer cells, highlighting the significance of cytosolic RNA delivery.
- R4F-LNP also proved its therapeutic potential for treating drugresistant cancers by delivering RNA interference to novel genetic targets.
- this study demonstrated the feasibility of using R4F-LNP to improve siRNA efficacy through cytosolic delivery, which advances undruggable diseases treatment using RNA interference and holds great potentials for enhancing efficacy of mRNA-based gene therapy.
Abstract
In an aspect, there is provided a lipid nanoparticle for the delivery of RNA to a subject, the lipid nanoparticle comprising: at least one phospholipid; an ionisable or cationic lipid; a PEG-lipid; at least one peptide, the peptide comprising an amino acid sequence capable of forming at least one amphipathic α-helix; and the RNA; wherein the components a), b), c), d) and e) associate to form the lipid nanoparticle.
Description
LIPID NANOPARTICLE FOR THE DELIVERY OF RNA
RELATED APPLICATIONS
This application claims priority to U.S. Provisional Application No. 63/347,051 filed on May 31 , 2022, which is incorporated herein by reference in its entirety.
FIELD OF THE INVENTION
The invention relates to lipid nanoparticles and more particularly to lipid nanoparticles that deliver RNA to a subject.
BACKGROUND OF THE INVENTION
Many cancers show metastasis and poor clinical outcome due to drug resistance: around 50-60% of colorectal cancer (CRC) patients develope unresectable liver and lung metastases and respond poorly to chemo/targeted therapy 1; Nearly 20% of castration-resistant prostate cancer (CRPC) patients become resistant to androgen signaling targeted therapy and acquire a more aggressive metastatic neuroendocrine PCa (NEPC) phenotype, more than 80% of which present with liver metastasis and with a median survival of less than one year from diagnosis 23. Hence, there is an urgent need to identify novel druggable targets and new therapeutic modalities beyond traditional chemotherapy.
RNA platforms are an exciting addition to the toolkit of targeted gene therapies. They function through the delivery of curative RNAs to the cell cytosol, where they regulate expression level of critical disease-related RNA transcripts or proteins.45 This delivery is mediated by vehicles that protect RNAs from their otherwise rapid degradation in viva, Lipid nanoparticles (LNP) are one such vehicle. LNPs protect RNAs by housing RNAs within their core while circulating through the body. Upon reaching cells, LNPs are uptaken into endosomes, where they dissociate and subsequently release RNA into cytosols. This stabilization of LNPs has yielded clinical success in delivering siRNA (Onpattro®, 2018), 6 mRNA (COVID vaccines, 2020), 7 and CRISPR gene editing
tools (Phase I trial, 2021).8 However, current LNPs are still bottlenecked by extremely low RNA endosomal escape efficiency (e.g. 1-2% for siRNA delivered) after LNP endocytosis.9 10 Consequently, >95% of RNAs are degraded in the lysosomes or being exocytosed,11 severely impairing their therapeutic efficacy. Thus, novel LNP systems are needed that boost RNA cytosolic delivery and improve RNA therapeutics to reach their potential.
Scavenger receptor class B type I (SR-B1) is an integral membrane glycoprotein receptor that plays a crucial role in the metabolism of high-density lipoprotein (HDL) and permits the direct cytosolic influx of the lipid core with no corresponding lysosomal degradation.12 SR-B1 is upregulated in many cancer cell lines.13 For example, SR-B1 high expression was observed in PCa versus benign prostate, as well as in NEPC versus CRPC,14 and elevated SR-B1 has been associated to PCa aggressiveness.15 Besides, increased SRB1 expression in liver metastasis from CRC and breast cancer have also been reported.16 17 Due to its upregulation in many cancer cell lines and capacity to induce cytosolic cargo delivery, SRBI becomes a promising surface receptor for targeted cancer therapy with RNA interference. Previously, our lab reported that by incorporating Apolipoprotein A-1 (ApoA-1) mimetic peptide R4F into HDL-like nanoparticles, enhanced cytosolic siRNA delivery and in vivo oncogene knockdown have been observed 18 19. However, this delivery platform is limited by extra cholesterol modification on siRNA to enable siRNA incorporation onto nanoparticle’s lipid membrane via cholesterol overhang, which makes hydrophilic siRNA double strands facing outwards of nanoparticle surface, thus less protected and highly detachable during in vivo circulation.
SUMMARY OF THE INVENTION
In an aspect, there is provided a lipid nanoparticle for the delivery of RNA to a subject, the lipid nanoparticle comprising: (a) at least one phospholipid; (b) an ionisable or cationic lipid; (c) a PEG-lipid; (d) at least one peptide, the peptide comprising an amino acid sequence capable of forming at least one amphipathic a-helix; and (e) the RNA; wherein the components a), b), c), d) and e) associate to form the lipid nanoparticle.
In a further aspect, there is provided a method of delivering RNA to a subject, the method comprising administering to the subject the lipid nanoparticle described herein.
In a further aspect, there is provided the lipid nanoparticle described herein, for use in the delivery of RNA to a subject.
In a further aspect, there is provided a use of the lipid nanoparticle described herein, in the preparation of a medicament for treating a disease or condition, wherein the RNA treats said disease or condition. In a further aspect, there is provided a use of the lipid nanoparticle described herein, in the preparation of a medicament for treating a disease or condition wherein the lipid nanoparticle treats said disease or condition.
In a further aspect, there is provided a pharmaceutical composition comprising the lipid nanoparticle described herein in a pharmaceutically acceptable carrier.
BRIEF DESCRIPTION OF FIGURES
These and other features of the preferred embodiments of the invention will become more apparent in the following detailed description in which reference is made to the appended drawings wherein:
Figure 1 shows (A) Schematic illustration of siRNA encapsulation, LNP synthesis and R4F modification. (B) Transmission electronic microscopy images of R4F-LNP. (C) Number-based size distribution of R4F-LNP measured by dynamic light scattering. (D) Circular dichroism spectrum of conventional LNP and R4F-LNP, affirming the secondary structures assembled on the R4F-LNP.
Figure 2 shows (A) Intracellular delivery profile of R4F-LNP and conventional LNP in PC3-Luc6 at 6 and 24 h post-incubation. R4F-LNP displayed stronger cytosolic distribution of siRNA signal. Fluorescence was pseudocolored in green for FAM- labelled siRNA, Magenta for porphyrin-lipid. Scale bar: 20 pm. (B) Intracellular delivery profile of R4F-LNP in Idl(mSR-BI) (high SR-B1 expressing, top panel) cells and ldlA-7 (low SR-B1 expression, bottom panel) cells. R4F-LNP were more effectively uptaken by SR-B1 (+) vs SR-B1 (-) cells. Fluorescence was pseudocolored in blue for Hoechst 33342, green for FAM-labelled siRNA, and Magenta for porphyrin-lipid. Images on the most right hand are the overlay of previous channels. Scale bar: 40 pm.
Figure 3 shows in vitro luciferase knockdown by R4F-LNP and conventional LNP. (A) PC3-Luc6 cells were seeded in 96-well plates and treated for 48 hours with the
indicated doses of siLuc or siCtrl in different formulations. The bioluminescence was captured by Xenogene imaging system. (B) Normalized bioluminescence expression from each treatment group based on cell viability. **: p < 0.0021 ; ****: p < 0.0001. (C) Viability of cells treated by each formulation.
Figure 4 shows cell uptake of R4F-LNP and convention LNP measured by flow cytometry. PC3-Luc6 were incubated with both formulations for 6 and 24 h before analyzed by flow cytometer for single cell fluorescence from porphyrin-lipid (A) and FAM-siRNA (B). After 24 h incubation, no significant difference in cellular uptake was observed between formulations.
Figure 5 shows (A) Experimental design of R4F-LNP siRNA treatment in mouse liver metastasis model. (B) Representative images of the NOD/SCID mouse livers harvested 16 days after treatment with R4F-LNP loaded with different sequences. Quantification of the liver weight at the experimental endpoint in mouse liver metastasis model was shown on the right.
DETAILED DESCRIPTION
In the following description, numerous specific details are set forth to provide a thorough understanding of the invention. However, it is understood that the invention may be practiced without these specific details.
In this study, utilizing siRNA as a model RNA therapeutics, we developed a novel peptide-functionalized lipid nanoplatform which facilitates RNA cytosolic delivery through SRBI-mediated uptake pathway to address the RNA endosomal escape challenge of LNP. We incorporated ApoA-1 mimetic R4F peptide (Ac- FAEKFKEAVKDYFAKFWD) into the FDA-approved LNP formulation to enable clinically used LNP formulation with cytosolic siRNA delivery functions without changing its high, stable siRNA loading capacity (R4F-LNP; Figure 1A). The RNAs are encapsulated in the core of lipid nanoparticles and further shielded by a R4F peptide network thereby being well protected during in vivo circulation. We demonstrated that R4F-LNP improved siRNA delivery over original LNP formulation with a 3~4-fold enhancement in luciferase reporter gene knockdown efficacy. Confocal microscopy imaging revealed that R4F-LNP significantly altered siRNA intracellular
delivery profile, showing a transition from classic organelle-oriented endocytosis to direct cytosolic distribution. Furthermore, we have demonstrated the therapeutic potency of R4F-LNP in an in vivo colorectal cancer (CRC) liver metastasis model by targeting a novel CRC gene target we identified recently.20 Overall, this R4F-LNP holds great potential to enhance the efficacy of RNA therapeutics by delivering nucleic acids directly to cell cytosols which provides an effective therapeutic option for undruggable disease targets.
In an aspect therefore, there is provided a lipid nanoparticle for the delivery of RNA to a subject, the lipid nanoparticle comprising: at least one phospholipid; an ionisable or cationic lipid; a PEG-lipid; at least one peptide, the peptide comprising an amino acid sequence capable of forming at least one amphipathic a-helix; and the RNA; wherein the components a), b), c), d) and e) associate to form the lipid nanoparticle.
Suitable scaffold peptides may be selected from the group consisting of Class A, H, L and M a-helices or a fragment thereof. Suitable scaffold peptides may also comprise a reversed peptide sequence of the Class A, H, L and M amphipathic a-helices or a fragment thereof, as the property of forming an amphipathic a-helix is determined by the relative position of the amino acid residues within the peptide sequence.
In one embodiment, the scaffold peptide has an amino acid sequence comprising consecutive amino acids of an apolipoprotein, preferably selected from the group consisting of apoB-100, apoB-48, apoC, apoE and apoA.
The "amino acids" used in this invention, and the term as used in the specification and claims, include the known naturally occurring protein amino acids, which are referred to by both their common three letter abbreviation and single letter abbreviation. See generally Synthetic Peptides: A User's Guide, G A Grant, editor, W.H. Freeman & Co., New York, 1992, the teachings of which are incorporated herein by reference, including the text and table set forth at pages 11 through 24. As set forth above, the term "amino acid" also includes stereoisomers and modifications of naturally occurring protein amino acids, non-protein amino acids, post-translationally modified amino acids, enzymatically synthesized amino acids, derivatized amino acids, constructs or structures designed to mimic amino acids, and the like. Modified and unusual amino acids are described generally in Synthetic Peptides: A User's Guide, cited above; Hruby J, Al-obeidi F and Kazmierski W: Biochem J 268:249-262,1990; and Toniolo
C: Int J Peptide Protein Res 35:287-300,1990; the teachings of all of which are incorporated herein by reference.
"Alpha-helix" is used herein to refer to the common motif in the secondary structure of proteins. The alpha helix (a-helix) is a coiled conformation, resembling a spring, in which every backbone N-H group donates a hydrogen bond to the backbone C=O group of the amino acid four residues earlier. Typically, alpha helices made from naturally occurring amino acids will be right handed but left handed conformations are also known.
“Amphipathic” is a term describing a chemical compound possessing both hydrophilic and hydrophobic properties. An amphipathic alpha helix is an often-encountered secondary structural motif in biologically active peptides and proteins and refers to an alpha helix with opposing polar and nonpolar faces oriented along the long axis of the helix.
Examples of small amphipathic helix peptides include those described in WO 09/073984.
Methods for detecting and characterizing protein domains with putative amphipathic helical structure are set forth in Segrest, J. P. et al. in PROTEINS: Structure, Function, and Genetics (1990) 8:103-117, the contents of which are incorporated herein by reference. Segrest et al. have identified seven different classes of amphipathic helices and have identified peptides/proteins associated with each class. Of the seven different classes there are four lipid-associating amphipathic helix classes (A, H, L, and M). Of these, Class A, the designated apolipoprotein class, possesses optimal properties for forming phospholipid-based particles.
As used herein, “phospholipid” is a lipid having a hydrophilic head group having a phosphate group and hydrophobic lipid tail.
PEG-lipid or PEG lipid is also known as PEGylated lipid, and is a class of PEG derivatives that is attached with lipid moiety such as, but not limited to, DMG, DSPE, DPPE, or DMPE.
In some embodiments, the lipid nanoparticle is a monolayer particle comprising the phospholipid, the PEG-lipid and the peptide having encapsulated therein the RNA and ionisable lipid.
In some embodiments, the at least one amphipathic a-helix or peptide is between 6 and 30 amino acids in length. Preferably, the at least one amphipathic a-helix or peptide is between 8 and 28 amino acids in length, between 10 and 24 amino acids in length, between 11 and 22 amino acids in length, between 14 and 21 amino acids in length, between 16 and 20 amino acids in length, or 18 amino acids in length.
In some embodiments, the peptide is 2F, 4F, the reverse sequence of 2F, or the reverse sequence of 4F.
In some embodiments, the total lipid to peptide molar ratio is 0.5-10%.
In some embodiments, the phospholipid is selected from the group consisting of phosphatidylcholines, phosphatidylethanolamines, phosphatidic acid, phosphatidylglycerols and combinations thereof. Preferably, the phospholipid is selected from the group consisting of 1 ,2-dipalmitoyl-sn-glycero-3-phosphatidic acid (DPPA), 1 ,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC), 1 ,2-distearoyl-sn- glycero-3-phosphocholine (DSPC), 1 ,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1 ,2-dibehenoyl-sn-glycero-3-phosphocholine (DBPC), 1 ,2-diarachidoyl-sn- glycero-3-phosphatidylcholine (DAPC), 1 ,2-dilignoceroyl-sn-glycero-3- phosphatidylcholine(DLgPC), 1 ,2-dipalmitoyl-sn-glycero-3-[phosphor-rac-(1 -glycerol)] (DPPG) and combinations thereof.
In some embodiments, a headgroup of the ionisable or cationic lipid comprises an amine, guanidine or heterocyclic group. Preferably, the headgroup is a primary amine, secondary amine, tertiary amine, quarternary amine, guanidine, pryidinium or imdazolium.
In some embodiments, the ionisable or cationic lipid comprises 1-4 hydrophobic tails that are independently saturated or unsaturated.
In some embodiments, the ionisable or cationic lipid comprises a linker between the headgroup and tail comprising an ether, carbomate, ester, amide, disulfide, thiol, ketal, phosphate or urea.
In some embodiments, the ionisable or cationic lipid is L319, YSK12-C4, CL4H6, SM- 102, ALC-0315, Arcturus 10q, DLin-DMA-MC3, or ssPalmO-Phe.
In some embodiments, the ionisable lipid is present at a 20-90% molar ratio in the lipid nanoparticle.
In some embodiments, the PEG-lipid has a carbon chain length of C14-C22.
In some embodiments, the PEG-lipid has a molecular weight ranging from about 1000 to about 5000.
In some embodiments, the PEG-lipid is 1 ,2-dimyristoyl-rac-glycero-3- methoxypolyethylene glycol-2000 (DMG-PEG2000), N-(methoxypolyethylene glycol 5000 carbamoyl)-1 ,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine (MPEG5000- DPPE), 1 ,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000 (DMPE-PEG2000), 1 ,2-distearoyl-sn-glycero-3-phosphoethanolamine- N- [methoxy(polyethylene glycol)-2000 (DSPE-PEG2000), Polyoxyethylene 40 stearate (PEG40S) or combinations thereof.
In some embodiments, the PEG-lipid is present at a 0.5-10% molar ratio in the lipid nanoparticle
In some embodiments, the RNA is a therapeutic RNA. Preferably, the RNA is a siRNA, mRNA, shRNA, miRNA, tRNA, circRNA or saRNA.
In some embodiments, the lipid nanoparticle further comprises a sterol, a sterol ester, or combinations thereof. Preferably, the sterol or a sterol ester is cholesterol, cholesterol oleate or an unsaturated cholesterol-ester.
In some embodiments, the lipid nanoparticle comprises Dlin-MC3-DMA, DSPC, cholesterol, and DMG-PEG2000.
In some embodiments, the lipid nanoparticle further comprises a targeting or homing molecule.
“Targeting molecule” is any molecule that can direct the nanovesicle to a particular target, for example, by binding to a receptor or other molecule on the surface of a targeted cell. Targeting molecules may be proteins, peptides, nucleic acid molecules, saccharides or polysaccharides, receptor ligands or other small molecules. The degree of specificity can be modulated through the selection of the targeting molecule. For example, antibodies typically exhibit high specificity. These can be polyclonal,
monoclonal, fragments, recombinant, or single chain, many of which are commercially available or readily obtained using standard techniques.
In some embodiments, the lipid nanoparticle further comprises a porphyrinphospholipid conjugate.
In some embodiments, in the lipid nanoparticle is 20-70 nm in diameter, 30-60 nm in diameter or 40-50 nm in diameter.
In a further aspect, there is provided a method of delivering RNA to a subject, the method comprising administering to the subject the lipid nanoparticle described herein.
In a further aspect, there is provided the lipid nanoparticle described herein, for use in the delivery of RNA to a subject.
In a further aspect, there is provided a use of the lipid nanoparticle described herein, in the preparation of a medicament for treating a disease or condition, wherein the RNA treats said disease or condition.
In a further aspect, there is provided a pharmaceutical composition comprising the lipid nanoparticle described herein in a pharmaceutically acceptable carrier.
As used herein, “pharmaceutically acceptable carrier1' means any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. Examples of pharmaceutically acceptable carriers include one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition. Pharmaceutically acceptable carriers may further comprise minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers, which enhance the shelf life or effectiveness of the pharmacological agent.
As used herein, “therapeutically effective amount' refers to an amount effective, at dosages and for a particular period of time necessary, to achieve the desired therapeutic result. A therapeutically effective amount of the pharmacological agent may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the pharmacological agent to elicit a desired response in
the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of the pharmacological agent are outweighed by the therapeutically beneficial effects.
The advantages of the present invention are further illustrated by the following examples. The examples and their particular details set forth herein are presented for illustration only and should not be construed as a limitation on the claims of the present invention.
EXAMPLES
Methods and Materials
Materials: 1 ,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), cholesterol and 1 ,2- dimyristoyl-rac-glycero3-methoxy(poly(ethylene glycol))-2000 (DMG-PEG2000), were purchased from Avanti Polar Lipids (Alabaster, AL, USA). DLin-MC3-DMA was purchased from Nanosoft Polymers (NO, USA). The ApoA-1 mimetic R4F peptide, Ac- FAEKFKEAVKDYFAKFWD, was purchased from GL Biochem Ltd. (Shanghai, China). Porphyrin-lipid was synthesized by the previously reported methods.21
Small Interfering RNA: Luciferase targeting siLuc and scrambled siCtrl were both purchased from Horizon Discovery (USA). siLuc (sense, 5'-GAU UAU GUC CGG UUA UGU AdTsdT-3'; antisense, 5'-UAC AUA ACC GGA CAU AAU CdTsdT-3'). FAM-siLuc (sense, 5'-FAM-GAU UAU GUC CGG UUA UGU AdTsdT-3'; antisense, 5'-UAC AUA ACC GGA CAU AAU CdTsdT-3'). siCtrl (sense, 5’-UUC UCC GAA CGU GUC ACG UdTsdT-3’; antisense, 5’-ACG UGA CAC GUU CGG AGA AdTsdT-3’). siRNA targeting ARHGEF2 was purchased from GenePharma (Shanghai, China). siARHGEF2 (sense, 5’-GGA UCU ACC UGU CAC UAC Utt-3’; antisense, 5’- AGUAGUGACAGGUAGAUCCag-3’).
Synthesis and Characterization of R4F-LNP: R4F-LNP was synthesized via a two- step process: 1) siRNA-loaded LNP formulations were formed using microfluidic rapid mixing method as previously reported.22 Lipids were mixed in ethanol at a molar ratio of DLin-MC3-DMA I DSPC I Cholesterol I DMG-PEG2000 = 50/10/38.5/1.5. siRNA was dissolved in 25mM sodium acetate buffer (pH=4.0). The two phases were mixed through herringbone microfluidic chips (microfluidic ChipShop, Germany) at a volumetric flow rate ratio of 3:1 (aqueous to ethanol). The mixed solution was dialyzed
against PBS 7.4 overnight. Afterwards LNPs were passed through 0.22 um filter and concentrated using centrifuge. For imaging studies, DSPC in the formulation was fully replaced by porphyrin-lipid and siRNA was fluorescein-labelled siRNA was used. Formulations were prepared with the same method as described above. 2) R4F- peptide was dissolved in PBS and added dropwise into pre-formed LNP solutions under gentle shaking at a lipid/R4F ratio of 3:1. The mixture was kept at 4 °C overnight. Next, the solution was centrifuged at 12000 rpm for 20 min and filtered with 0.22 um filter before use. The hydrodynamic size and dispersity of R4F-LNP was characterized with a Zetasizer Nano ZS (Malvern Instruments). The morphology of R4F-LNP was checked by Hitachi HT7800 electron microscopy with 2% uranyl acetate negative staining. siRNA encapsulation efficiency was measured by Ribogreen Assay based on manufacture’s protocol (Thermofisher). The circular dichroism spectrum was measured with Jasco J-815 CD spectrophotometer (Jasco, Easton, MD). Formulations diluted in PBS was subjected to scanning from 250 nm to 190 nm at 0.1 nm data pitch with background subtracted.
Cell Culture: PC3-luc6 cells were purchased from Caliper LifeSciences and cultured in Ham's F-12K (Kaighn's) Medium (supplemented with 10% FBS). Chinese hamster ovary (CHO) Idl(mSR-BI) and ldlA-7 cells were gifts from Dr. Monty Krieger (Massachusetts Institute of Technology, Cambridge, MA). ldlA-7 cells were cultured in Hams F-12 medium (Gibco) supplemented with penicillin-streptomycin (1 v/v %), FBS (5 v/v%), and L-glutamine (2 mM). Idl(mSR-BI) cells were cultured under similar conditions as ldlA-7 with the addition of 300 ug/mL of G418 Geneticin. HCT116 were purchased from ATCC and cultured in McCoy's 5a Medium Modified with 10% FBS. All cell cultures were maintained in a 37 °C humidified incubator under 5% CO2.
Confocal Microscopy and Cell-Uptake Studies: For confocal imaging studies, PC3- Iuc6, Idl(mSR-BI) and ldlA-7 cells were seeded into 8-well coverglass-bottom chambers (Nunc LabTek, Sigma-Aldrich, Rochester, NY) at a cell-seeding density of 2 x 104 cells per well. After 48 h of incubation, R4F-LNP or pyro-LNP were added at a concentration of 4 pM based on porphyrin and incubated for 6 and 24 h. Cells were washed twice with culturing medium before imaging. Fluorescence images were captured by Stimulated emission depletion (STED) microscopy (Leica, Germany) using a 63x oil objective lens. Customized filter settings were used to collect signal from porphyrin-lipid (excitation: 660 nm; emission: 670 nm - 765 nm), and FAM-labelled siRNA (excitation: 488 nm; emission: 507-580 nm). Laser power and detector gain
adjustment were kept consistent between the time points. For flow cytometry experiments, PC3-Luc6 cells were seeded at 4 x 104 cells per well into 24-well plates for 48 h. Then cells were incubated with R4F-LNP or pyro-LNP at a concentration of 50 nM siRNA (1.6 pM porphyrin) for 6 or 24 h. Afterwards, the treated cells were washed and centrifuged before analyzed by cytoFLEX S (Beckman Coulter, USA). Porphyrin fluorescence was collected at APC channel while FAM fluorescence was collected at FITC channel.
In Vitro Luciferase Knockdown: PC3-Luc6 cells were seeded at 4 x 103 cells per well into 96-well plates for 48 h. Then cells were incubated with R4F-LNP or pyro-LNP at different siRNA concentration for 48 h, after which the cells were washed twice with culturing medium and replaced with medium that contains 0.5 mg.mL-1 alamarBlue (Invitrogen) for viability measurement: cells were incubated for 2 h, after which fluorescence emission was collected using a CLARIOstar microplate reader (BMG LABTECH) (excitation of 540/8 nm and emission of 590/8 nm). Luciferase expression of PC3-Luc6 on the same plate was evaluated through bioluminescence: after alamarBlue assay, 5 pL D-luciferin solution (25 mM) was added into each well (100 pL medium), after which the bioluminescence was collected by IVIS Spectrum In Vivo Imaging System (PerkinElmer). Bioluminescence intensity of each well was further normalized by its viability before analysis.
In Vivo Liver Metastasis Treatment: The mouse model of liver metastasis was established by intrasplenic injection of HCT116 cells into NOD/SCID mouse. In the intrasplenic injection model, enrofloxacin in the drinking water as a prophylactic oral antibiotic was administered to mice 72 h prior to surgery. Mice were anesthetized with Buprenorphine Sustained-Release (SR). ~1 cm incision was made in the left upper abdominal wall and ~1 cm incision was made in the peritoneum to expose the mouse spleen. Moistened sterile cotton swab was used to gently exteriorize the spleen. HCT116 cells (0.75x106 cells per mouse) were injected into each mouse with a 27G needle. After the spleen was returned to the abdominal cavity, the muscle layer and skin were closed, and subcutaneous fluid therapy was administered. The mice were sacrificed 3~4 weeks after intrasplenic injection. The mouse liver was excised and fixed for histological examination. The liver metastasis was assessed either by the number of visible liver metastatic nodules or the liver weight and the proportion of tumor metastases in the mouse liver when tumor nodules were indistinguishable.
Results and Discussion
Synthesis and Characterization of R4F-LNP. R4F-LNP was formulated by coating ApoA-1 mimetic peptide R4F onto the preformed LNP following a process illustrated in Figure 1A. Briefly, LNP nanoparticles were prepared through rapid mixing of siRNA and lipid components via a microfluidic system, followed by raising pH from 4.0 to 7.4 with dialysis process. The R4F peptides were then added dropwisely into the preformed LNPs in PBS condition with a R4F/lipid ratio of 1 :3 and subsequently incubated at 4°C overnight to form stable R4F-LNPS. The morphology of R4F-LNP was disclosed by transmission electronic microscopy imaging (Figure 1 B), showing spherical structures with homogenous size distribution at ~50 nm. The size of R4F- LNP was also confirmed by dynamic light scattering measurement, showing a monodispersed peak at 45.22 ± 2.18 nm, with a polydispersity index (PDI) of 0.146 (Figure 1C). The size of R4F-LNP is in line with that of the LNP (~ 40-50 nm) before adding R4F,23 suggesting a surface coating of R4F doesn’t change the particles size. Moreover, the circular dichroism (CD) spectra demonstrated a significantly enhanced signature peak in 200 -230 nm wavelength in R4F-LNP versus LNP, suggesting a stable secondary structure formed by peptide incorporation onto LNP surface (Figure 1 D). In addition, R4F-LNP demonstrated >95% siRNA encapsulation efficiency as determined by Ribogreen assay, indicating incorporation of R4F peptide into preformed LNP enabling stable and high payload of siRNA loading. siRNA Intracellular Delivery Profile. To investigate the cellular uptake profile of R4F- LNP, both R4F-LNP and conventional LNP were formulated with porphyrin-lipid dopped onto lipid bilayer and FAM dye labelled on siRNA as markers for lipids and siRNA. First, we compared the intracellular siRNA delivery pattern of both formulations in PC3-Luc6 cells using confocal microscopy. As shown in Figure 2A, conventional LNP treated cells (bottom panels) displayed well-colocalized FAM-siRNA and porphyrin-lipid signals with punctate pattern in cells after 6 h incubation, indicating LNP entrapment in acidic organelles (i.e. endosomes, lysosomes) by clathrin-mediated endocytosis as well as macropinocytosis.10 In contrast, R4F-LNP treated cells showed strong siRNA fluorescence (FAM, green colour) in both cytosols and organelles. The FAM signal in the cytosols was well diffused. Interestingly, the porphyrin lipid fluorescence (magenta colour) was observed on cellular membrane in addition to co-
localization with FAM-siRNA in the same organelles with a punctate pattern. These data suggested that two delivery pathways existed in R4F-LNP delivery: 1) Classic LNP endocytosis that directed nanoparticle entrapment in the organelles. 2) SR-B1 mediated uptake pathway after R4F incorporation onto LNP, which enabled direct siRNA delivery into cellular cytosol while leaving the lipid components on the cellular membrane. This delivery pattern is also consistent with our previous reported R4F- constrained HDL-like nanoparticles for cytosolic siRNA delivery.18 192425 Besides, the confocal images at 24 h incubation also support the enhanced cytosolic delivery by R4F-LNP. Therefore, R4F incorporation on LNP membrane can alter the siRNA intracellular uptake pathway from organelles to cytosols, which can potentially improve siRNA therapeutic efficacy.
Next, we incubated R4F-LNP with Idl(mSR-BI) (SR-B1 overexpressing) and ldlA-7 (SR-B1 deficient) cells for 24 h to examine the SR-B1 -dependent cellular uptake. After 24 h incubation, cells were imaged under confocal microscopy. As displayed in Figure 2B, Idl(mSR-BI) cells demonstrated markedly higher uptake with stronger fluorescence in both FAM-siRNA and porphyrin-lipid channels when compared with ldlA-7 cells. Significant cytosolic diffusion of siRNA signal was also observed in the Idl(mSR-BI) cells, suggesting that R4F-LNP was mainly taken up through SR-B1 receptor mediated pathway.
In Vitro Luciferase Knockdown: After the investigation of the cytosolic siRNA delivery profile of R4F-LNP, we validated its influence on siRNA knockdown efficacy. Luciferase targeting siRNA (siLuc) and scramble control siRNA (siCtrl) were encapsulated into R4F-LNP and conventional LNP, respectively. Formulations were subsequently incubated with PC3-Luc6 cells to validate the level of luciferase gene knockdown. Bioluminescence intensity was decreased in a dose-dependent manner in the cells treated by both R4F-LNP and conventional LNP while negligible signal reduction was observed in LNP-siCtrl treated wells (Figure 3A, B). Notably, enhanced bioluminescence signal reduction was achieved by R4F-LNP treatment when compared to the conventional LNP across all siRNA concentrations applied. Specifically, R4F-LNP caused ~70% decrease of bioluminescence expression in PC3- Luc6 cells at 10 nM siLuc concentration whereas only ~20% knockdown was achieved by conventional LNP without R4F coating, resulting in 3-4 fold therapeutic enhancement. Given no obvious difference in cell viability caused by R4F-LNP and conventional LNP, the significantly enhanced luciferase knockdown by R4F-LNP is
possibly contributed by cytosolic delivery of siRNA that was demonstrated in previous confocal imaging studies.
To further validate whether there’s enhancement of total siRNA uptake amount by R4F-LNP, which can also contribute to improved siRNA efficacy, we performed a flow cytometry experiment to quantitatively compare the uptake difference between R4F- LNP and conventional LNP in PC3-Luc6 cells. Both single cell fluorescent signals from porphyrin-lipid (Figure 4A) and FAM-siRNA (Figure 4B) were collected and quantified. The results demonstrated that there’s a slight enhancement of delivery by R4F-LNP compared to conventional LNP at short/early time incubation (6h). When cells were treated for 24 h, no significant difference in uptake amount was noticed. Given that the in vitro luciferase knockdown study shown in Figure 3 was conducted with 48h incubation, the improvement in siRNA knockdown efficacy by R4F-LNP is mainly due to the intracellular distribution of siRNA into cytosol, rather than the enhancement of delivery amount, thus demonstrating the importance of cytosolic delivery for siRNA efficacy.
In Vivo Liver Metastasis Treatment: After in vitro validation for the improved RNAi efficacy and cytosolic delivery by R4F-LNP, next we performed in vivo gene knockdown experiment to evaluate therapeutic potential of R4F-LNP. Recently, we have identified a novel therapeutic gene target for drug-resistant CRC, ARHGEF2, which is a highly upregulated m6A reader in CRC that promotes CRC tumorigenesis and metastasis.20 As liver metastasis from CRC showed upregulated SR-B1 level, therefore, R4F-LNP with SR-B1 targeting ability and cytosolic siRNA delivery feature is promising for treating CRC-induced liver metastasis. The mouse liver metastasis model was established by injecting 7.5x105 HCT116 cells intrasplenically into each NOD/SCID mouse. At twelve days after surgery, the mice were randomly defined into two groups and received 1.2 mg/kg of R4F-LNP siCtrl or R4F-LNP siARHGEF2-1 intravenously, every four days for total four doses (at day12, day 16, day20, day24) (Figure 5A). The results showed that R4F-LNP siARHGEF2-1 significantly reduced colorectal liver metastases compared to the R4F-LNP siCtrl treated group as evidenced by significantly reduced liver weight by two-fold (P <0.05, student’s t-test; Figure 5B), which is an indicator of liver metastasis level
Discussion: In summary, this study first demonstrates the therapeutic potential of applying R4F peptide to FDA-approved lipid nanoparticle formulations for enhancing
cytosolic delivery of siRNA therapeutics. The R4F-LNP exhibited a combined delivery pattern enabling direct delivery of a portion of siRNA into cancer cell cytosol via a SR- B1 mediated internalization pathway. A 3~4-fold enhancement of RNAi therapeutic efficacy by R4F-LNP was demonstrated on an in vitro luciferase expressing prostate cancer cells, highlighting the significance of cytosolic RNA delivery. Using a mice liver metastasis model, R4F-LNP also proved its therapeutic potential for treating drugresistant cancers by delivering RNA interference to novel genetic targets. Overall, this study demonstrated the feasibility of using R4F-LNP to improve siRNA efficacy through cytosolic delivery, which advances undruggable diseases treatment using RNA interference and holds great potentials for enhancing efficacy of mRNA-based gene therapy.
Although preferred embodiments of the invention have been described herein, it will be understood by those skilled in the art that variations may be made thereto without departing from the spirit of the invention or the scope of the appended claims. All documents disclosed herein, including those in the following reference list, are incorporated by reference.
Reference List
1. Engstrand, J., Nilsson, H., Stromberg, C., Jonas, E. & Freedman, J. Colorectal cancer liver metastases - a population-based study on incidence, management and survival. BMC Cancer 18, 78 (2018).
2. Aggarwal, R. et al. Clinical and genomic characterization of treatment- emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. Journal of Clinical Oncology 36, 2492 (2018).
3. Palmgren, J. S., Karavadia, S. S. & Wakefield, M. R. Unusual and Underappreciated: Small Cell Carcinoma of the Prostate. Seminars in Oncology 34, 22-29 (2007).
4. Damase, T. R. et al. The Limitless Future of RNA Therapeutics. Front Bioeng Biotechnol 9, 628137 (2021).
5. Wang, F., Zuroske, T. & Watts, J. K. RNA therapeutics on the rise. Nature Reviews Drug Discovery 19, 441-442 (2020).
6. Akinc, A. et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nature Nanotechnology 14, 1084-1087 (2019).
7. Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid- 19 Vaccine. N Engl J Med 383, 2603-2615 (2020).
8. Gillmore, J. D. et al. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin
Amyloidosis. The New England Journal of Medicine 10 (2021) doi: 10.1056/NEJMoa2107454.
9. Kim, J., Eygeris, Y., Gupta, M. & Sahay, G. Self-assembled mRNA vaccines. Advanced Drug Delivery Reviews 170, 83-112 (2021).
10. Gilleron, J. et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol 31 , 638-646 (2013).
11 . Sahay, G. et al. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol 31 , 653-658 (2013).
12. Rodrigueza, W. V. et al. Mechanism of Scavenger Receptor Class B Type I- mediated Selective Uptake of Cholesteryl Esters from High Density Lipoprotein to Adrenal Cells *. Journal of Biological Chemistry 274, 20344-20350 (1999).
13. Rajora, M. A. & Zheng, G. Targeting SR-BI for Cancer Diagnostics, Imaging and Therapy. Front Pharmacol 7 , 326 (2016).
14. Pandey, M., Cuddihy, G., Gordon, J. A., Cox, M. E. & Wasan, K. M. Inhibition of Scavenger Receptor Class B Type 1 (SR-B1) Expression and Activity as a Potential Novel Target to Disrupt Cholesterol Availability in Castration-Resistant Prostate Cancer. Pharmaceutics 13, 1509 (2021).
15. Gordon, J. A. et al. Upregulation of Scavenger Receptor B1 Is Required for Steroidogenic and Nonsteroidogenic Cholesterol Metabolism in Prostate Cancer. Cancer Res 79, 3320-3331 (2019).
16. Zhang, K.-L. et al. Organ-specific cholesterol metabolic aberration fuels liver metastasis of colorectal cancer. Theranostics 11 , 6560-6572 (2021).
17. Medina-Echeverz, J. et al. Harnessing High Density Lipoproteins to Block Transforming Growth Factor Beta and to Inhibit the Growth of Liver Tumor Metastases. PLOS ONE 9, e96799 (2014).
18. Yang, M. et al. Efficient cytosolic delivery of siRNA using HDL-mimicking nanoparticles. Small 7, 568-73 (2011).
19. Lin, Q. et al. Efficient systemic delivery of siRNA by using high-density lipoprotein-mimicking peptide lipid nanoparticles. Nanomedicine (Lond) 7, 1813-25 (2012).
20. Wang, S. et al. N6-Methyladenosine Reader YTHDF1 Promotes ARHGEF2 Translation and RhoA Signaling in Colorectal Cancer. Gastroenterology 162, 1183— 1196 (2022).
21. Lovell, J. F. et al. Porphysome nanovesicles generated by porphyrin bilayers for use as multimodal biophotonic contrast agents. Nature materials 10, 324-332 (2011).
22. Belliveau, N. M. et al. Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA. Molecular Therapy - Nucleic Acids 1 , e37 (2012).
23. Kulkarni, J. A., Witzigmann, D., Chen, S., Cullis, P. R. & van der Meel, R. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics. Acc Chem
Res 52, 2435-2444 (2019).
24. Zhang, Z. et al. Biomimetic nanocarrier for direct cytosolic drug delivery. Angew Chem Int Ed Engl 48, 9171-5 (2009).
25. Lin, Q. et al. Imaging the cytosolic drug delivery mechanism of HDL-like nanoparticles. Pharm Res 31 , 1438-49 (2014).
Claims
1. A lipid nanoparticle for the delivery of RNA to a subject, the lipid nanoparticle comprising: a) at least one phospholipid; b) an ionisable or cationic lipid c) a PEG-lipid; d) at least one peptide, the peptide comprising an amino acid sequence capable of forming at least one amphipathic a-helix; and e) the RNA; wherein the components a), b), c), d) and e) associate to form the lipid nanoparticle.
2. The lipid nanoparticle of claim 1 , being a monolayer particle comprising the phospholipid, the PEG-lipid and the peptide having encapsulated therein the RNA and ionisable lipid.
3. The lipid nanoparticle of claim 1 or 2, wherein the peptide is selected from the group consisting of Class A, H, L and M amphipathic a-helices, fragments thereof, and peptides comprising a reversed peptide sequence of said Class A, H, L and M amphipathic a-helices or fragments thereof.
4. The lipid nanoparticle of any one of claims 1-3, wherein the at least one amphipathic a-helix or peptide is between 6 and 30 amino acids in length.
5. The lipid nanoparticle of claim 4, wherein the at least one amphipathic a-helix or peptide is between 8 and 28 amino acids in length, between 10 and 24 amino acids in length, between 11 and 22 amino acids in length, between 14 and 21 amino acids in length, between 16 and 20 amino acids in length, or 18 amino acids in length.
6. The lipid nanoparticle of claim 3, wherein the peptide is 2F, 4F, the reverse sequence of 2F, or the reverse sequence of 4F.
7. The lipid nanoparticle of claim 3, wherein the peptide is R4F peptide (Ac- FAEKF KEAVKDYFAKF WD) .
8. The lipid nanoparticle of claim 6 or 7, wherein the total lipid to peptide molar ratio is 0.5-10%.
9. The lipid nanoparticle of any one of claims 1-8, wherein the phospholipid is selected from the group consisting of phosphatidylcholines, phosphatidylethanolamines, phosphatidic acid, phosphatidylglycerols and combinations thereof.
10. The lipid nanoparticle of claim 9, wherein the phospholipid is selected from the group consisting of 1 ,2-dipalmitoyl-sn-glycero-3-phosphatidic acid (DPPA), 1 ,2- dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC), 1 ,2-distearoyl-sn- glycero-3-phosphocholine (DSPC), 1 ,2-dimyristoyl-sn-glycero-3- phosphocholine (DMPC), 1 ,2-dibehenoyl-sn-glycero-3-phosphocholine (DBPC), 1 ,2-diarachidoyl-sn-glycero-3-phosphatidylcholine (DAPC), 1 ,2- dilignoceroyl-sn-glycero-3-phosphatidylcholine(DLgPC), 1 ,2-dipalmitoyl-sn- glycero-3-[phosphor-rac-(1 -glycerol)] (DPPG) and combinations thereof.
11. The lipid nanoparticle of any one of claims 1-10, wherein a headgroup of the ionisable or cationic lipid comprises an amine, guanidine or heterocyclic group.
12. The lipid nanoparticle of claim 11 , wherein the headgroup is a primary amine, secondary amine, tertiary amine, quarternary amine, guanidine, pryidinium or imdazolium.
13. The lipid nanoparticle of any one of claims 11-12, wherein the ionisable or cationic lipid comprises 1-4 hydrophobic tails that are independently saturated or unsaturated.
14. The lipid nanoparticle of any one of claims 11-13, wherein the ionisable or cationic lipid comprises a linker between the headgroup and tail comprising an ether, carbomate, ester, amide, disulfide, thiol, ketal, phosphate or urea.
15. The lipid nanoparticle of any one of claims 1-10, wherein the ionisable or cationic lipid is L319, YSK12-C4, CL4H6, SM-102, ALC-0315, Arcturus 10q, DLin-DMA-MC3, or ssPalmO-Phe.
16. The lipid nanoparticle of any one of claims 1-15, wherein the ionisable lipid is present at a 20-90% molar ratio in the lipid nanoparticle.
17. The lipid nanoparticle of any one of claims 1-16, wherein the PEG-lipid has a carbon chain length of C14-C22.
18. The lipid nanoparticle of any one of claims 1-17, wherein the PEG-lipid has a molecular weight ranging from about 1000 to about 5000.
19. The lipid nanoparticle of any one of claims 1-16, wherein the PEG-lipid is 1 ,2- dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (DMG-PEG2000), N-(methoxypolyethylene glycol 5000 carbamoyl)- 1 ,2-dipalmitoyl-sn-glycero-3- phosphatidylethanolamine (MPEG5000-DPPE), 1 ,2-dimyristoyl-sn-glycero-3- phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000 (DMPE- PEG2000), 1 ,2-distearoyl-sn-glycero-3-phosphoethanolamine- N- [methoxy(polyethylene glycol)-2000 (DSPE-PEG2000), Polyoxyethylene 40 stearate (PEG40S) or combinations thereof.
20. The lipid nanoparticle of any one of claims 1-19, wherein the PEG-lipid is present at a 0.5-10% molar ratio in the lipid nanoparticle
21. The lipid nanoparticle of any one of claims 1-20, wherein the RNA is a therapeutic RNA.
22. The lipid nanoparticle of claim 21 , wherein the RNA is a siRNA, mRNA, shRNA, miRNA, tRNA, circRNA or saRNA.
23. The lipid nanoparticle of any one of claims 1-22, wherein the lipid nanoparticle further comprises a sterol, a sterol ester, or combinations thereof.
24. The lipid nanoparticle of claim 23, wherein the sterol or a sterol ester is cholesterol, cholesterol oleate or an unsaturated cholesterol-ester.
25. The lipid nanoparticle of claim 1 , wherein the lipid nanoparticle comprises Dlin- MC3-DMA, DSPC, cholesterol, and DMG-PEG2000.
26. The lipid nanoparticle of any one of claims 1-25, wherein the lipid nanoparticle further comprises a targeting or homing molecule.
27. The lipid nanoparticle of any one of claims 1-26, wherein the lipid nanoparticle further comprises a porphyrin-phospholipid conjugate.
28. The lipid nanoparticle of any one of claims 1-27, wherein the lipid nanoparticle is 20-70 nm in diameter, 30-60 nm in diameter or 40-50 nm in diameter.
29. A method of delivering RNA to a subject, the method comprising administering to the subject the lipid nanoparticle of any one of claims 1-28.
30. The lipid nanoparticle of any one of claims 1-28, for use in the delivery of RNA to a subject.
31. Use of the lipid nanoparticle of any one of claims 1-28, in the preparation of a medicament for treating a disease or condition, wherein the RNA treats said disease or condition.
32. A pharmaceutical composition comprising the lipid nanoparticle of any one of claims 1-28 in a pharmaceutically acceptable carrier.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263347051P | 2022-05-31 | 2022-05-31 | |
US63/347,051 | 2022-05-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023230711A1 true WO2023230711A1 (en) | 2023-12-07 |
Family
ID=89026437
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2023/050735 WO2023230711A1 (en) | 2022-05-31 | 2023-05-29 | Lipid nanoparticle for the delivery of rna |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023230711A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2708719A1 (en) * | 2007-12-12 | 2009-06-18 | University Health Network | High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles |
CA3079403A1 (en) * | 2017-10-16 | 2019-04-25 | Aadigen, Llc | Peptides and nanoparticles for intracellular delivery of mrna |
WO2020016242A1 (en) * | 2018-07-17 | 2020-01-23 | Centre National De La Recherche Scientifique | Peptides for use as cell-penetrating peptides |
-
2023
- 2023-05-29 WO PCT/CA2023/050735 patent/WO2023230711A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2708719A1 (en) * | 2007-12-12 | 2009-06-18 | University Health Network | High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles |
CA3079403A1 (en) * | 2017-10-16 | 2019-04-25 | Aadigen, Llc | Peptides and nanoparticles for intracellular delivery of mrna |
WO2020016242A1 (en) * | 2018-07-17 | 2020-01-23 | Centre National De La Recherche Scientifique | Peptides for use as cell-penetrating peptides |
Non-Patent Citations (12)
Title |
---|
CROMBEZ LAURENCE, MORRIS MAY, DESHAYES SEBASTIEN, HEITZ FREDERIC, DIVITA GILLES: "Peptide-Based Nanoparticle for Ex Vivo and In Vivo Dug Delivery", CURRENT PHARMACEUTICAL DESIGN, BENTHAM SCIENCE PUBLISHERS, NL, vol. 14, no. 34, 1 December 2008 (2008-12-01), NL , pages 3656 - 3665, XP093121624, ISSN: 1381-6128, DOI: 10.2174/138161208786898842 * |
CRUZ WILLIAM, HUANG HUANG, BARBER BRIAN, PASINI ELISA, DING LILI, ZHENG GANG, CHEN JUAN, BHAT MAMATHA: "Lipoprotein‐Like Nanoparticle Carrying Small Interfering RNA Against Spalt‐Like Transcription Factor 4 Effectively Targets Hepatocellular Carcinoma Cells and Decreases Tumor Burden", HEPATOLOGY COMMUNICATIONS, vol. 4, no. 5, 1 May 2020 (2020-05-01), pages 769 - 782, XP093121616, ISSN: 2471-254X, DOI: 10.1002/hep4.1493 * |
DESHAYES ET AL.: "Self Assembling Peptide-Based Nanoparticles for siRNA Delivery in Primary Cell Lines", SMALL, vol. 8, no. 14, 2012, pages 2184 - 2188, XP055042538, DOI: 10.1002/smll.201102413 * |
FARKHAN1 ET AL.: "Cell penetrating peptides: Efficient vectors for delivery of nanoparticles, nanocarriers, therapeutic and diagnostic molecules", PEPTIDES, vol. 57, 2014, pages 78 - 94, XP028854855, DOI: 10.1016/j.peptides.2014.04.015 * |
GROS EDWIGE, DESHAYES SEBASTIEN, MORRIS MAY C., ALDRIAN-HERRADA GUDRUN, DEPOLLIER JULIEN, HEITZ FREDERIC, DIVITA GILLES: "A non-covalent peptide-based strategy for protein and peptide nucleic acid transduction", BIOCHIMICA ET BIOPHYSICA ACTA, ELSEVIER, AMSTERDAM, NL, vol. 1758, no. 3, 1 March 2006 (2006-03-01), AMSTERDAM, NL , pages 384 - 393, XP093121626, ISSN: 0005-2736, DOI: 10.1016/j.bbamem.2006.02.006 * |
JIANG GAN, CHEN HUAN, HUANG JIALIN, SONG QINGXIANG, CHEN YAOXING, GU XIAO, JIANG ZHENHUAN, HUANG YUKUN, LIN YINGYING, FENG JUNFENG: "Tailored Lipoprotein‐Like miRNA Delivery Nanostructure Suppresses Glioma Stemness and Drug Resistance through Receptor‐Stimulated Macropinocytosis", ADVANCED SCIENCE, vol. 7, no. 5, 1 March 2020 (2020-03-01), pages 1903290, XP093012213, ISSN: 2198-3844, DOI: 10.1002/advs.201903290 * |
KONATE KARIDIA, DUSSOT MARION, ALDRIAN GUDRUN, VAISSIÈRE ANAÏS, VIGUIER VÉRONIQUE, NEIRA ISABEL FERREIRO, COUILLAUD FRANCK, VIVÈS : "Peptide-Based Nanoparticles to Rapidly and Efficiently "Wrap ’n Roll" siRNA into Cells", BIOCONJUGATE CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 30, no. 3, 20 March 2019 (2019-03-20), US , pages 592 - 603, XP093121617, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.8b00776 * |
LIN QIAOYA, CHEN JUAN, JIN HONGLIN, NG KENNETH K, YANG MI, CAO WEIGUO, DING LILI, ZHANG ZHIHONG, ZHENG GANG: "Efficient systemic delivery of siRNA by using high-density lipoprotein-mimicking peptide lipid nanoparticles", NANOMEDICINE, FUTURE MEDICINE LTD., LONDON, GB, vol. 7, no. 12, 1 December 2012 (2012-12-01), GB , pages 1813 - 1825, XP009551485, ISSN: 1743-5889, DOI: 10.2217/nnm.12.73 * |
PÄRNASTE LY, ARUKUUSK PIRET, LANGEL KENT, TENSON TANEL, LANGEL ÜLO: "The Formation of Nanoparticles between Small Interfering RNA and Amphipathic Cell-Penetrating Peptides", MOLECULAR THERAPY-NUCLEIC ACIDS, CELL PRESS, US, vol. 7, 1 June 2017 (2017-06-01), US , pages 1 - 10, XP093121621, ISSN: 2162-2531, DOI: 10.1016/j.omtn.2017.02.003 * |
QIAN ET AL.: "Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages", ACS NANO, vol. 11, 2017, pages 9536 - 9549, XP055676639, DOI: 10.1021/acsnano.7b05465 * |
RATHNAYAKE P. V. G. M., GUNATHUNGE B. G. C. M., WIMALASIRI P. N., KARUNARATNE D. N., RANATUNGA R. J. K. U.: "Trends in the Binding of Cell Penetrating Peptides to siRNA: A Molecular Docking Study", JOURNAL OF BIOPHYSICS, vol. 2017, 21 February 2017 (2017-02-21), pages 1 - 12, XP093121623, ISSN: 1687-8000, DOI: 10.1155/2017/1059216 * |
YANG, ET AL.: "Efficient Cytosolic Delivery of siRNA Using HDL-Mimicking Nanoparticlers", SMALL, vol. 7, no. 5, 1 January 2011 (2011-01-01), pages 568 - 573, XP055982049 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Campbell et al. | Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors | |
Zhou et al. | Tumour‐derived extracellular vesicle membrane hybrid lipid nanovesicles enhance siRNA delivery by tumour‐homing and intracellular freeway transportation | |
Li et al. | Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor | |
US10973765B2 (en) | Cell membrane-derived nanovesicles and use thereof | |
KR101198715B1 (en) | Asymmetric liposomes with higher encapsulation efficiency of nucleic acids and hydrophilic anion chemicals | |
Kong et al. | Cationic solid lipid nanoparticles derived from apolipoprotein-free LDLs for target specific systemic treatment of liver fibrosis | |
CN101439182B (en) | Somatostatin receptor mediated tumor-targeted medicament composition | |
TWI362931B (en) | Irinotecan formulation | |
Ringgaard et al. | Tumor repolarization by an advanced liposomal drug delivery system provides a potent new approach for chemo-immunotherapy | |
Liu et al. | Camouflaged Hybrid Cancer Cell‐Platelet Fusion Membrane Nanovesicles Deliver Therapeutic MicroRNAs to Presensitize Triple‐Negative Breast Cancer to Doxorubicin | |
Tang et al. | Liposomes co-modified with cholesterol anchored cleavable PEG and octaarginines for tumor targeted drug delivery | |
Wang et al. | paclitaxel-loaded PEG-PE–based micellar nanopreparations targeted with tumor-specific landscape phage fusion protein enhance apoptosis and efficiently reduce tumors | |
Dong et al. | Dual‐loaded liposomes tagged with hyaluronic acid have synergistic effects in triple‐negative breast cancer | |
Wan et al. | In Vivo Delivery of siRNAs Targeting EGFR and BRD4 Expression by Peptide-Modified Redox Responsive PEG–PEI Nanoparticles for the Treatment of Triple-Negative Breast Cancer | |
Li et al. | Controlled and Targeted Drug Delivery by a UV‐responsive Liposome for Overcoming Chemo‐resistance in Non‐Hodgkin Lymphoma | |
Shao et al. | Targeting the TMPRSS2/ERG fusion mRNA using liposomal nanovectors enhances docetaxel treatment in prostate cancer | |
WO2008038291A1 (en) | Combination of liposomal anti-cancer drugs and lysosome/endosome ph increasing agents for therapy | |
Dreaden et al. | RNA‐peptide nanoplexes drug DNA damage pathways in high‐grade serous ovarian tumors | |
JP2010059064A (en) | Drug delivery complex | |
US20150297749A1 (en) | Low-density lipoprotein analogue nanoparticles, and composition comprising same for targeted diagnosis and treatment of liver | |
AU2008295666B2 (en) | Improved liposomes and uses thereof | |
Zhang et al. | Combined self-assembled hendeca-arginine nanocarriers for effective targeted gene delivery to bladder cancer | |
Yuan et al. | Transforming Cancer-Associated Fibroblast Barrier into Drug Depots to Boost Chemo-Immunotherapy in “Shooting Fish in a Barrel” Pattern | |
US11141491B2 (en) | PH-sensitive lipid nanoparticles for encapsulation of anticancer drugs and microRNA and use thereof | |
CN110898231A (en) | Functionalized larotaxel liposome and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23814590 Country of ref document: EP Kind code of ref document: A1 |